Evidence map›Paper›PMID 36952190›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Applying CRISPR-Cas9 Genome Editing to Study Genes Involved in Peroxisome Biogenesis or Peroxisomal Functions.

Serhii Chornyi, Janet Koster, Hans R Waterham

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Serhii ChornyiDepartment of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Amsterdam UMC - University of Amsterdam, AZ, Amsterdam, the Netherlands.
Janet KosterDepartment of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Amsterdam UMC - University of Amsterdam, AZ, Amsterdam, the Netherlands.
Hans R WaterhamDepartment of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Amsterdam UMC - University of Amsterdam, AZ, Amsterdam, the Netherlands. h.r.waterham@amsterdamumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development and application of the CRISPR-Cas9 technology for genome editing of mammalian cells have opened up a wealth of possibilities for genetically modifying and manipulating human cells, and use in functional studies or therapeutic approaches.Here we describe the approach that we have been using successfully to generate multiple human cell lines with targeted (partial) gene deletions, i.e., knockout cells, or human cells with modified genomic nucleotide sequences, i.e., knock-in cells, in genes encoding known or putative proteins involved in peroxisome biogenesis or peroxisomal functions.

Indexed as

CRISPR-Cas SystemsGene EditingAnimalsBase SequenceGenomeHumansMammalsPeroxisomesCRISPR-Cas9Gene deletionGene disruptionGene editingGene knockoutPEX genes

Identifiers

PMID36952190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.